Assessment of the activity of a novel nociceptin/orphanin FQ analogue at recombinant human nociceptin/orphanin FQ receptors expressed in Chinese hamster ovary cells

  1. Lookup NU author(s)
  2. Dr Kathleen Wright
Author(s)Wright KE, McDonald J, Barns TA, Rowbotham DJ, Guerrini R, Calo G, Lambert DG
Publication type Article
JournalNeuroscience Letters
Year2003
Volume346
Issue3
Pages145-148
ISSN (print)0304-3940
ISSN (electronic)1872-7972
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
The neuropeptide nociceptin/orphanin FQ (N/OFQ) is the endogenous ligand for the nociceptin receptor (NOP). In an attempt to identify high potency NOP agonists for use in the brain we have compared the activity of a novel N/OFQ analogue [Phe1Ψ(CH2-O)Gly2]N/OFQ(1-13)NH2 ([F/G-O]) with the existing [Phe1Ψ(CH2-NH)Gly2]N/OFQ(1-13)NH2 ([F/G]). Both peptides are modified between the first two N-terminal amino acids and are further compared with the agonist template N/OFQ(1-13)NH2 in [3H]N/OFQ binding, GTPγ[35S] binding and cAMP inhibition studies using Chinese hamster ovary cells expressing the recombinant human NOP. All peptides displaced [3H]N/OFQ, stimulated GTPγ[35S] binding and inhibited cAMP formation. In [3H]N/OFQ binding and GTPγ[35S] binding the rank order affinity and potency was N/OFQ(1-13)NH2>[F/G-O]>[F/G]. In GTPγ[35S] binding [F/G] was a clear partial agonist with intrinsic activity (Emax stimulation factor, mean±SEM, n=4) of 7.75±1.02 compared with N/OFQ(1-13)NH2 of 11.13±1.76. The efficacy of [F/G-O] (10.17±1.88) approached that of the full agonist N/OFQ(1-13)NH2. Downstream, at the level of cAMP formation, all peptides were full agonists with the following rank order potency: N/OFQ(1-13)NH2>[F/G-O]=[F/G]. The enhanced potency and intrinsic activity of the novel [F/G-O] modification makes this an interesting peptide for further in vivo analysis.
PublisherElsevier
URLhttp://dx.doi.org/10.1016/S0304-3940(03)00518-4
DOI10.1016/S0304-3940(03)00518-4
Actions    Link to this publication